Outcomes included the incidence of interval CRC in FIT‐negative participants (<47 μg Hb/g feces [μg/g]), FIT‐sensitivity, and the probability of detecting an interval CRC by fecal hemoglobin concentration (f‐Hb). The gene discussed is GSTM1; the disease is colorectal carcinoma.